FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a new long-acting acylated analogue of the oxyntomodulin peptide with dual agonism for GLP-1 and glucagon receptors (dual agonism GLP-1-R/glucagon-R), and to a pharmaceutical composition containing it for the prevention and treatment of obesity and overweight body or non-insulin dependent diabetes mellitus, accompanied by obesity and overweight.
EFFECT: acylated oxyntomodulin peptide analogue of the invention has dual GLP-1/glucagon agonism and excellently extended in vivo half-life, and a pharmaceutical composition containing it is useful for treating metabolic diseases such as obesity and diabetes.
8 cl, 6 dwg, 10 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE ANALOG OF ACYLATED OXYNTOMODULIN | 2018 |
|
RU2752787C1 |
| NOVEL OXYNTOMODULIN DERIVATIVES AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM FOR TREATING OBESITY | 2012 |
|
RU2739209C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| COMPOSITION FOR TREATING HYPERLIPIDEMIA CONTAINING AN OXYNTOMODULIN DERIVATIVE | 2013 |
|
RU2768853C1 |
| LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS | 2018 |
|
RU2779314C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| CONJUGATE CONTAINING OXINTOMODULIN AND IMMUNOGLOBULIN FRAGMENT, AND ITS APPLICATION | 2012 |
|
RU2733544C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| STRUCTURES HAVING SIRP-ALPHA DOMAIN OR ITS VERSION | 2016 |
|
RU2740672C2 |
